| Key Takeaways: Wegovy is semaglutide at a higher dose than Ozempic – FDA-approved specifically for weight loss, not diabetes. Clinical trials show participants lost an average of 15% of body weight over 68 weeks with the injection, and 13.6% with the new once-daily pill. Wegovy launched in India in June 2025, and the semaglutide patent expired in March 2026, opening the market to Indian generic manufacturers. |
If you have heard about Wegovy for weight loss and wondered how it differs from Ozempic, whether a pill version exists, or when you can get it in India.
This guide answers all of it, using published clinical trial data and regulatory sources.
1. What Exactly Is Wegovy, and How Does It Work in the Body?
Wegovy is the brand name for semaglutide (the active drug in Wegovy) at the 2.4 mg dose, a once-weekly injectable medication approved by the U.S. Food and Drug Administration (FDA) in June 2021 for chronic weight management in adults.
Semaglutide belongs to a class of medicines called glucagon-like peptide-1 (GLP-1) receptor agonists. It mimics a hormone your gut naturally releases after eating — one that signals to the brain that you are full.
According to the NCBI StatPearls review on semaglutide, semaglutide works through three interlocking pathways:
- It stimulates insulin release when blood sugar rises
- It suppresses glucagon (the hormone that raises blood sugar)
- It slows gastric emptying, meaning food leaves the stomach more slowly — keeping you full for longer
The net effect: appetite decreases, calorie intake drops, and the body draws down stored fat. Wegovy is prescribed alongside a reduced-calorie diet and increased physical activity. It is a medical tool, not a replacement for lifestyle changes.
| Who qualifies for Wegovy?Adults with a BMI of 30 or above (obesity)Adults with a BMI of 27 or above and at least one weight-related condition (such as high blood pressure, high cholesterol, or type 2 diabetes)Adolescents aged 12 and older with obesity (FDA approved in 2022) |
2. Wegovy vs. Ozempic: Same Molecule, Very Different Purpose
This is the question that confuses most people — and the answer is both yes and no.
Wegovy and Ozempic both contain semaglutide, made by the same manufacturer, Novo Nordisk. The active ingredient is chemically identical. But the two drugs are not interchangeable in a clinical context.
| Feature | Wegovy | Ozempic |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| FDA-approved indication | Chronic weight management; cardiovascular risk reduction in obesity | Type 2 diabetes; cardiovascular risk reduction in T2D |
| Maximum weekly injection dose | 2.4 mg | 2.0 mg |
| Available as a pill? | Yes (25 mg oral, approved Dec 2025) | No |
| Pen type | Single-use prefilled pen | Multi-dose pen (4-8 doses) |
| Weight loss as primary goal? | Yes — purpose-built for it | No — weight loss is a secondary effect |
| Approved for adolescents? | Yes (age 12+, obesity) | No |
The NCBI review on Wegovy summarises it precisely: the primary difference beyond dose is regulatory indication. Ozempic is approved for diabetes.
Wegovy is approved for obesity. Some clinicians prescribe Ozempic off-label for weight loss, but Wegovy is the drug that was designed, dosed, and trialled specifically for that purpose.
The higher maintenance dose of Wegovy (2.4 mg vs. 2.0 mg weekly) produces meaningfully greater appetite suppression and more consistent fat loss over time, according to prescribing data reviewed by Cleveland Clinic.
| One important noteOzempic is not FDA-approved for weight loss. Prescribing it off-label for that purpose is a clinical decision your doctor makes individually. If weight management is your documented goal, Wegovy is the approved pathway. |
3. What Do the Clinical Trials Actually Show About Weight Loss?
Wegovy’s approval rests on the STEP (Semaglutide Treatment Effect in People with Obesity) clinical programme, which consists of four large phase 3 randomised controlled trials run by Novo Nordisk and submitted to the FDA.
The landmark trial, STEP 1, enrolled 1,961 adults with overweight or obesity over 68 weeks. Published in the New England Journal of Medicine:
| Outcome | Wegovy Group (2.4 mg) | Placebo Group |
|---|---|---|
| Mean body weight reduction | 14.9% | 2.4% |
| Participants losing 5% or more of body weight | 86% | 32% |
| Participants losing 15% or more of body weight | 50% | 5% |
| Average absolute weight lost | ~15 kg | ~2.6 kg |
Real-world data published in PMC (SCOPE study) found that patients achieved approximately 6% weight reduction at 3 months and 12% at 7 months in routine clinical settings — tracking closely with the trial outcomes.
One important caveat from the STEP 1 extension data: participants who stopped semaglutide regained roughly two-thirds of the lost weight within one year of discontinuation.
Appetite returns within days to weeks after stopping. This positions Wegovy as a long-term management tool rather than a short course of treatment.
4. The New Pill Version: What Is the Wegovy Oral Form and How Does It Differ?
On 22 December 2025, the FDA approved the Wegovy pill — oral semaglutide 25 mg, taken once daily — making it the first oral GLP-1 receptor agonist approved specifically for weight loss.
This is a significant development. Injections remain the most common format, but a meaningful share of people either have needle anxiety, find weekly injections inconvenient, or simply prefer a tablet as part of a daily routine. The pill form expands access to a different group of patients.
| Feature | Wegovy Injection | Wegovy Pill |
|---|---|---|
| Dose | 2.4 mg subcutaneous injection | 25 mg oral tablet |
| Frequency | Once weekly | Once daily |
| FDA approval date | June 2021 | December 22, 2025 |
| Key trial | STEP 1 | OASIS 4 |
| Mean weight loss (adherent participants) | ~14.9% at 68 weeks | 16.6% at 64 weeks |
| Participants losing 20%+ body weight | ~30% | ~33% |
| Dose escalation range (for pill) | 0.25 mg to 2.4 mg over 16-20 weeks | 1.5 mg to 4 mg to 9 mg to 25 mg over 12 weeks |
| US launch | June 2021 | Early January 2026 |
The OASIS 4 trial, the phase 3 basis for the pill’s approval and published in the New England Journal of Medicine, enrolled 307 adults with obesity or overweight.
With full treatment adherence, oral semaglutide 25 mg delivered 16.6% mean weight loss at 64 weeks, compared with 2.7% in the placebo group. More than 76% of participants on the pill achieved at least 5% body weight reduction, versus 31% on placebo.
According to Novo Nordisk, the weight loss achieved with the pill is comparable to the injection form, making it a genuine alternative rather than a downgrade.
The pill also carries the same cardiovascular risk-reduction indication as the injection.
| How to take the Wegovy pill correctlyTake it once daily, at least 30 minutes before the first food, drink, or other oral medication of the daySwallow whole with plain water only (no more than 120 mL). Do not crush, chew, or split the tablet.This specific timing and method is critical — semaglutide’s oral absorption depends on it.Always follow the instructions of your prescribing physician. |
5. What Are the Common and Serious Side Effects of Wegovy?
Wegovy side effects are well-documented across the STEP and OASIS trial programmes. Most side effects are gastrointestinal in nature and most pronounced during the dose-escalation phase, when your dose is being gradually increased over the first few months.
| Side Effect | Reported Incidence (Adults) | Typical Timing |
|---|---|---|
| Nausea | 44% | Most common during dose escalation (first 4 months) |
| Vomiting | 24% | Early treatment phase |
| Diarrhoea | 30% | Early treatment phase |
| Constipation | 24% | Can persist longer than other GI effects |
| Abdominal pain | 20% | Usually transient |
| Headache | 14% | Variable |
| Fatigue | 11% | Usually early in treatment |
| Hair loss | Reported | More common with higher doses |
Source: FDA Wegovy prescribing information and the STEP programme trial data.
Serious Warnings to Know
Wegovy carries an FDA boxed warning for the risk of thyroid C-cell tumours. Animal studies showed dose-dependent tumour formation.
Whether this risk applies in humans has not been established, but the drug is contraindicated in patients with:
- A personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Additional serious adverse events observed in clinical use include acute pancreatitis (persistent severe abdominal pain radiating to the back is a warning sign), gallbladder disease including gallstones, and acute kidney injury from dehydration caused by vomiting or diarrhoea.
For most people, gastrointestinal side effects improve as the body adjusts to the medication. Slowing down dose escalation on which Wegovy’s prescribing schedule is built around is the primary strategy for minimising them.
| When to contact your doctor promptlySevere or persistent abdominal pain (particularly if radiating to the back)Lump or swelling in the neck, hoarseness, or difficulty swallowingSigns of an allergic reaction: facial swelling, breathing difficulty, rapid heart ratePersistent vomiting leading to inability to keep fluids down |
6. How Is Wegovy Dosed, and How Long Does It Take to Work?
Wegovy uses a step-up dosing schedule, starting low and gradually increasing over several months. This approach significantly reduces early gastrointestinal side effects and gives the body time to adjust.
| Phase | Injection Dose | Duration |
|---|---|---|
| Initiation | 0.25 mg once weekly | Weeks 1-4 |
| Escalation Step 1 | 0.5 mg once weekly | Weeks 5-8 |
| Escalation Step 2 | 1.0 mg once weekly | Weeks 9-12 |
| Escalation Step 3 | 1.7 mg once weekly | Weeks 13-16 |
| Maintenance dose | 2.4 mg once weekly | Week 17 onwards |
Based on STEP 1 data, the steepest phase of weight loss occurs after reaching the maintenance dose — typically continuing from month 5 through approximately month 14, before plateauing.
At 3 months, real-world studies show approximately 6% body weight reduction. By 7 months, this typically reaches around 12%. Most clinical benefits accumulate over the full treatment period of at least one year.
The pill form (25 mg) follows a 12-week escalation from 1.5 mg up to the maintenance dose of 25 mg and then continues once daily long term.
7. Is Wegovy Available in India, and What Changed After March 2026?
Wegovy had its India launch in June 2025, brought forward by Novo Nordisk from an originally planned 2026 window, in response to rising demand and regulatory approvals.
In February 2025, India’s Central Drugs Standard Control Organisation (CDSCO) approved semaglutide 2.4 mg for cardiovascular risk reduction in adults with obesity or overweight which paved the path for the weight management indication.
India’s semaglutide landscape shifted significantly on 20 March 2026, when the active compound’s patent expired in the country.
This opened the door to generic manufacturing by Indian pharmaceutical companies, which means a broader range of semaglutide-based products will become available across price points through 2026.
| Milestone | Date |
|---|---|
| CDSCO approval for cardiovascular indication | February 2025 |
| Wegovy injection launched in India | June 2025 |
| Novo Nordisk price reduction on injection | November 2025 |
| Semaglutide patent expiry in India | 20 March 2026 |
| First Indian generic approvals (Sun Pharma, Zydus, Natco, Mankind) | December 2025 onwards |
According to a report by Business Today, over 40 Indian pharmaceutical companies are preparing to launch semaglutide versions, with 50+ brand names expected through 2026. Early entrants include Sun Pharma (Noveltreat), Zydus (Semaglyn, Mashema, Altreme), Natco Pharma, and Mankind Pharma (Samakind).
One clinical nuance specific to India: South Asian populations carry elevated cardiometabolic risk at lower BMI thresholds than the cutoffs used in Western trials.
Indian cardiologists have recommended that waist circumference, in addition to BMI, be used to identify who may benefit from semaglutide — a point noted in the CDSCO committee discussions, as reported by STAT News.
| Important: This is a prescription-only medication in IndiaWegovy and its generic equivalents require a valid prescription from a registered medical practitioner. Self-medication with semaglutide carries significant risk. Common side effects including nausea, vomiting, and dehydration require proper clinical monitoring.Always consult a qualified physician or endocrinologist before starting any GLP-1 medication. |
Bottom Line
Wegovy is semaglutide at a weight-loss-optimised dose — clinically distinct from Ozempic in its indication, dosing, and intent.
Across the STEP clinical programme, it demonstrated ~15% mean body weight reduction over 68 weeks, with a well-understood side effect profile manageable through gradual dose escalation.
The December 2025 FDA approval of the once-daily pill form expands options meaningfully — offering injection-comparable weight loss for people who prefer or need an oral route.
In India, the drug is now accessible and the patent landscape is shifting rapidly toward generic availability.
If you are considering semaglutide for weight management, speak with a qualified endocrinologist or internist about whether your BMI, waist circumference, and health history make you an appropriate candidate.
Frequently Asked Questions
Q1. What is Wegovy and how does it differ from Ozempic?
Ans. Wegovy is semaglutide at a 2.4 mg weekly injection dose, FDA-approved specifically for chronic weight management. Ozempic is the same molecule but at a lower maximum dose (2.0 mg weekly), approved for type 2 diabetes and cardiovascular risk reduction in diabetic patients.
Wegovy is purpose-built for obesity; Ozempic is built for diabetes with weight loss occurring as a secondary effect.
Q2. Is Wegovy available in India?
Ans. Yes. Novo Nordisk launched Wegovy in India in June 2025. Since the semaglutide patent expired in India in March 2026, generic versions from Indian manufacturers are also entering the market.
The drug remains prescription-only. Consult an endocrinologist or internist to determine clinical eligibility and access through proper medical channels.
Q3. What is the approved dose of Wegovy for weight loss?
Ans. The maintenance dose for the Wegovy injection is 2.4 mg once weekly, reached gradually over a 16-week dose-escalation schedule starting at 0.25 mg. For the once-daily pill, the maintenance dose is 25 mg, reached over 12 weeks.
Your prescribing physician determines the appropriate dose and escalation pace based on your individual response and tolerability.
Q4. How much weight can you expect to lose on Wegovy?
Ans. In the STEP 1 trial, participants lost a mean of 14.9% of body weight at 68 weeks with the injection. In the OASIS 4 trial of the pill form, adherent participants lost 16.6% at 64 weeks. Individual results vary significantly.
Stopping the medication is associated with substantial weight regain, which is why clinical guidelines position Wegovy as a long-term treatment.
Q5. Can you use Wegovy if you do not have diabetes?
Ans. Yes. Wegovy is approved for people with or without type 2 diabetes, provided BMI and other criteria are met. Unlike Ozempic, diabetes is not a prerequisite for Wegovy eligibility.
Adults with a BMI of 30 or above, or 27 or above with at least one weight-related comorbidity (high blood pressure, dyslipidaemia, or type 2 diabetes), may qualify. Talk with your doctor about your specific situation.
